Clene Inc (CLNN)
$0.3351
Insights on Clene Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 108.0K → 170.0K (in $), with an average increase of 36.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -2.41M → -10.17M (in $), with an average decrease of 320.7% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 110.8%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 334.8%
Performance
- $0.33$0.35$0.34
4.03%
Downside
Day's Volatility :5.56%
Upside
1.59%
- $0.25$1.09$0.34
26.47%
Downside
52 Weeks Volatility :77.06%
Upside
68.81%
Returns
| Period | Clene Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -28.75% | -0.4% | 0.0% |
6 Months | -30.62% | 9.6% | 0.0% |
1 Year | -66.02% | 3.9% | -1.3% |
3 Years | -96.48% | 12.8% | -22.1% |
Highlights
Market Capitalization | 44.8M |
Book Value | $0.1 |
Earnings Per Share (EPS) | -0.47 |
Wall Street Target Price | 5.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -5841.18% |
Return On Assets TTM | -52.33% |
Return On Equity TTM | -595.47% |
Revenue TTM | 654.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | -27.400000000000002% |
Gross Profit TTM | 447.0K |
EBITDA | -38.8M |
Diluted Eps TTM | -0.47 |
Quarterly Earnings Growth YOY | 0.61 |
EPS Estimate Current Year | -0.3 |
EPS Estimate Next Year | -0.28 |
EPS Estimate Current Quarter | -0.07 |
EPS Estimate Next Quarter | -0.08 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 1392.09%
Technicals Summary
Sell
Neutral
Buy
Clene Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Clene Inc | -22.56% | -30.62% | -66.02% | -96.48% | -96.3% |
 Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
 Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
 Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
 Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Clene Inc | 4.14 | NA | NA | -0.3 | -5.95 | -0.52 | NA | 0.1 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Clene Inc | Buy | $44.8M | -96.3% | 4.14 | 0.0% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
Company Information
clene has a new vision for a pharmaceutical future using therapeutic elements in clean, new nanoforms. our patented clean-surface nanosuspension™ (csn) technology produces clean-surface nanocrystals at commercially viable rates. by coupling high-purity metallic donor materials with high-purity water, csn unlocks the potential of therapeutic nanoparticles and represents a clean break from the standard paradigm of small-molecule drugs and large-molecule biologics.
Organization | Clene Inc |
Employees | 82 |
CEO | Mr. Robert Etherington MBA |
Industry | Healthcare |
